Ionis Pharmaceuticals annual operating expenses
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals Operating Expenses Growth & History (IONS)
Ionis Pharmaceuticals's operating expenses was $1.31B for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.31B | $140.5M | +12.02% |
| 2024 | 2024-12-31 | $1.17B | $36.8M | +3.25% |
| 2023 | 2023-12-31 | $1.13B | $148.8M | +15.13% |
| 2022 | 2022-12-31 | $983.4M | $153.6M | +18.52% |
| 2021 | 2021-12-31 | $829.8M | −$59.6M | −6.70% |
| 2020 | 2020-12-31 | $889.4M | $137.1M | +18.22% |
| 2019 | 2019-12-31 | $752.3M | $93.1M | +14.12% |
| 2018 | 2018-12-31 | $659.2M | $176.1M | +36.45% |
| 2017 | 2017-12-31 | $483.1M | $90.2M | +22.95% |
| 2016 | 2016-12-31 | $392.9M | $33.5M | +9.31% |
| 2015 | 2015-12-31 | $359.5M | $97.6M | +37.26% |
| 2014 | 2014-12-31 | $261.9M | $62.9M | +31.64% |
| 2013 | 2013-12-31 | $199.0M | $28.0M | +16.36% |
| 2012 | 2012-12-31 | $171.0M | $787,000 | +0.46% |
| 2011 | 2011-12-31 | $170.2M | $13.4M | +8.52% |
| 2010 | 2010-12-31 | $156.8M | $7.7M | +5.16% |
| 2009 | 2009-12-31 | $149.1M | $28.9M | +24.02% |
| 2008 | 2008-12-31 | $120.3M | — | — |
Ionis Pharmaceuticals quarterly operating expenses
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $367.5M | $59.4M | +19.29% |
| Q1 2026 | 2026-03-31 | $360.5M | $83.5M | +30.15% |
| Q4 2025 | 2025-12-31 | $417.8M | $80.4M | +23.83% |
| Q3 2025 | 2025-09-30 | $314.6M | $33.2M | +11.79% |
| Q2 2025 | 2025-06-30 | $308.1M | $20.9M | +7.28% |
| Q1 2025 | 2025-03-31 | $277.0M | $10.2M | +3.80% |
| Q4 2024 | 2024-12-31 | $337.4M | $6.8M | +2.05% |
| Q3 2024 | 2024-09-30 | $281.4M | −$3.9M | −1.36% |
| Q2 2024 | 2024-06-30 | $287.2M | $11.1M | +4.02% |
| Q1 2024 | 2024-03-31 | $266.9M | $23.5M | +9.67% |
| Q4 2023 | 2023-12-31 | $330.6M | −$29.3M | −8.14% |
| Q3 2023 | 2023-09-30 | $285.3M | $67.9M | +31.22% |
| Q2 2023 | 2023-06-30 | $276.1M | $61.5M | +28.67% |
| Q1 2023 | 2023-03-31 | $243.3M | $48.1M | +24.62% |
| Q4 2022 | 2022-12-31 | $359.9M | $140.5M | +64.04% |
| Q3 2022 | 2022-09-30 | $217.4M | $1.5M | +0.71% |
| Q2 2022 | 2022-06-30 | $214.6M | $18.8M | +9.60% |
| Q1 2022 | 2022-03-31 | $195.3M | −$5.7M | −2.86% |
| Q4 2021 | 2021-12-31 | $219.4M | −$93.5M | −29.89% |
| Q3 2021 | 2021-09-30 | $215.9M | $22.3M | +11.54% |
| Q2 2021 | 2021-06-30 | $195.8M | $1.5M | +0.76% |
| Q1 2021 | 2021-03-31 | $201.0M | $9.1M | +4.72% |
| Q4 2020 | 2020-12-31 | $312.9M | $79.9M | +34.30% |
| Q3 2020 | 2020-09-30 | $193.5M | $29.1M | +17.72% |
| Q2 2020 | 2020-06-30 | $194.3M | $13.0M | +7.17% |
| Q1 2020 | 2020-03-31 | $191.9M | $17.3M | +9.91% |
| Q4 2019 | 2019-12-31 | $233.0M | $51.7M | +28.51% |
| Q3 2019 | 2019-09-30 | $164.4M | $435,000 | +0.27% |
| Q2 2019 | 2019-06-30 | $181.3M | $13.2M | +7.88% |
| Q1 2019 | 2019-03-31 | $174.6M | $26.9M | +18.22% |
| Q4 2018 | 2018-12-31 | $181.3M | $7.3M | +4.22% |
| Q3 2018 | 2018-09-30 | $164.0M | $57.0M | +53.24% |
| Q2 2018 | 2018-06-30 | $168.0M | $62.2M | +58.78% |
| Q1 2018 | 2018-03-31 | $147.7M | $51.4M | +53.37% |
| Q4 2017 | 2017-12-31 | $174.0M | $54.8M | +45.97% |
| Q3 2017 | 2017-09-30 | $107.0M | $12.2M | +12.85% |
| Q2 2017 | 2017-06-30 | $105.8M | $18.4M | +21.08% |
| Q1 2017 | 2017-03-31 | $96.3M | $4.8M | +5.23% |
| Q4 2016 | 2016-12-31 | $119.2M | $4.7M | +4.09% |
| Q3 2016 | 2016-09-30 | $94.8M | −$2.4M | −2.51% |
| Q2 2016 | 2016-06-30 | $87.4M | $11.6M | +15.33% |
| Q1 2016 | 2016-03-31 | $91.5M | $19.6M | +27.27% |
| Q4 2015 | 2015-12-31 | $114.5M | $39.7M | +53.13% |
| Q3 2015 | 2015-09-30 | $97.3M | $31.7M | +48.36% |
| Q2 2015 | 2015-06-30 | $75.8M | $12.1M | +18.92% |
| Q1 2015 | 2015-03-31 | $71.9M | $14.1M | +24.36% |
| Q4 2014 | 2014-12-31 | $74.8M | $12.7M | +20.41% |
| Q3 2014 | 2014-09-30 | $65.6M | $16.5M | +33.54% |
| Q2 2014 | 2014-06-30 | $63.7M | $17.7M | +38.47% |
| Q1 2014 | 2014-03-31 | $57.8M | $16.1M | +38.56% |
| Q4 2013 | 2013-12-31 | $62.1M | $16.1M | +35.04% |
| Q3 2013 | 2013-09-30 | $49.1M | $9.4M | +23.82% |
| Q2 2013 | 2013-06-30 | $46.0M | $2.4M | +5.44% |
| Q1 2013 | 2013-03-31 | $41.7M | $45,000 | +0.11% |
| Q4 2012 | 2012-12-31 | $46.0M | −$5.0M | −9.85% |
| Q3 2012 | 2012-09-30 | $39.6M | −$3.4M | −7.86% |
| Q2 2012 | 2012-06-30 | $43.6M | $4.8M | +12.24% |
| Q1 2012 | 2012-03-31 | $41.7M | $4.4M | +11.90% |
| Q4 2011 | 2011-12-31 | $51.0M | $8.7M | +20.68% |
| Q3 2011 | 2011-09-30 | $43.0M | $5.5M | +14.53% |
| Q2 2011 | 2011-06-30 | $38.9M | −$3.3M | −7.81% |
| Q1 2011 | 2011-03-31 | $37.3M | $2.4M | +7.04% |
| Q4 2010 | 2010-12-31 | $42.3M | — | — |
| Q3 2010 | 2010-09-30 | $37.6M | $404,000 | +1.09% |
| Q2 2010 | 2010-06-30 | $42.2M | $6.4M | +17.74% |
| Q1 2010 | 2010-03-31 | $34.8M | — | — |
| Q3 2009 | 2009-09-30 | $37.2M | — | — |
| Q2 2009 | 2009-06-30 | $35.8M | — | — |
Ionis Pharmaceuticals operating expenses trends
Over the last five fiscal years, Ionis Pharmaceuticals's operating expenses increased from $889.4M to $1.31B, a change of $420.1M. The latest reported quarter, Q2 2026, shows $367.5M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗Community posts
Roche quantifies proteinuria reduction for Ionis-licensed sefaxersen
Ionis ($IONS) reported new detailed results from partner Roche’s Phase 3 IMAgINATION trial of sefaxersen in IgA nephropathy. The investigational monthly injection reduced urine protein-to-creatinine ratio by 43.1% versus placebo at 37 weeks ...
